Qiagen's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Qiagen NV (QGEN)

Q2 2012 Earnings Call

July 25, 2012 9:30 AM ET

Executives



Albert Fleury – Director, IR

Peer Schatz – CEO

Roland Sackers – CFO

Analysts



Daniel Wendorff – Commerzbank

Tycho Peterson – JP Morgan

Bill Quirk – Piper Jaffray

Pete – William Blair

Romain Zana – Exane BNP Paribas

Jeff Elliott – Robert W Baird

Doug Schenkel – Cowen & Co

Vamel Geven – Credit Suisse

Presentation



Operator

Ladies and gentlemen, thank you for standing by. Welcome to the QIAGEN Conference Call on the Q2 Results 2012. (Operator Instructions)

I would now like to turn the conference over to Albert Fleury, Director, Investor Relations and Corporate Finance NA. Please go ahead sir.

Albert Fleury

Compare to:
Previous Statements by QGEN
» QIAGEN's CEO Discusses 1Q 2012 Results - Earnings Call Transcript
» QIAGEN's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» QIAGEN's CEO Hosts Investor Day - Conference Call Transcript
» QIAGEN's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Thank you, operator. Good afternoon and welcome to the QIAGEN conference call to discuss our latest quarterly results. Joining me on the call are Peer Schatz, Chief Executive Officer; Roland Sackers, Chief Financial Officer; and John Gilardi, Vice President, Corporate Communications and Investor Relations. A copy of this announcement and the presentation for this conference call can be downloaded from the Investor Relations section of our webpage at www.qiagen.com.

Moving on to slide two, before I turn the call over to Peer, please keep in mind that the following discussions and responses to your questions reflect management’s view as of today, July 25, 2012. As we share information to help you better understand our business, we will make statements and provide responses that state our intention, beliefs, expectations, or predictions of the future. These constitute forward-looking statements for the purpose of the safe harbor provisions. They involve certain risks and uncertainties that could cause QIAGEN’s actual results to differ materially from those projected.

1 2 3 4 Next › Last »